<b>Conclusions:</b> These findings demonstrate that the <i>FKBP10</i> multi-epitope vaccine is structurally stable, immunogenic, and capable of engaging key innate immune receptors, supporting its potential as a promising immunotherapeutic candidate for synovial sarcoma. Here, FKBP10 is linked to synovial sarcoma.